The exciting research that may cure Parkinson’s
GeneCode, a pharmaceutical company, received a €16 million funding option from the European Innovation Council Accelerator last year to support the development of a novel drug designed to combat neurodegeneration in Parkinson's patients. Preliminary evidence suggests that the drug may alleviate symptoms, protect neurons from further damage, and help restore neurons for a healthier, longer life. The drug binds to receptors in the brain and sends chemical signals that stimulate dopamine production, which helps neurons with axons stay active and maintain synaptic connections with other neurons. GeneCode has almost completed animal experiments, but it still needs to certify that the drug can be consistently and safely produced to ensure future quality assurance and perform toxicology studies before the drug can begin clinical trials in humans.